416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819175473321607168 |
|---|---|
| author | Vivek Subbiah Ravi Murthy Alexander Guminski Ding Wang Vivek Bhadri Nam Bui Jose Mejia Oneto Kamalesh Sankhala M Wayne Saville Sangeetha Srinivasan Robert Steffner Nathan Yee |
| author_facet | Vivek Subbiah Ravi Murthy Alexander Guminski Ding Wang Vivek Bhadri Nam Bui Jose Mejia Oneto Kamalesh Sankhala M Wayne Saville Sangeetha Srinivasan Robert Steffner Nathan Yee |
| author_sort | Vivek Subbiah |
| collection | DOAJ |
| first_indexed | 2024-12-22T20:55:25Z |
| format | Article |
| id | doaj.art-c55cf2e4612745f8907f9de4fc8f5a4c |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T20:55:25Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-c55cf2e4612745f8907f9de4fc8f5a4c2022-12-21T18:12:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0416416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumorsVivek Subbiah0Ravi Murthy1Alexander Guminski2Ding Wang3Vivek Bhadri4Nam Bui5Jose Mejia Oneto6Kamalesh Sankhala7M Wayne Saville8Sangeetha Srinivasan9Robert Steffner10Nathan Yee11MD Anderson Cancer Center, Houston, TX, USAMD Anderson Cancer Center, Houston, TX, USA3Royal North Shore Hospital, St Leonards, Australia8Henry Ford Hospital, Detroit, MI, USA1Chris O’Brien Lifehouse, Camperdown, Australia2Stanford Cancer Institute, Palo Alto, CA, USA4Shasqi, Inc., San Francisco, CA, USA6Cedars-Sinai Angeles Clinic, Santa Monica, CA, USA4Shasqi, Inc., San Francisco, CA, USA4Shasqi, Inc., San Francisco, CA, USA7Stanford Medicine, Redwood City, CA, USA4Shasqi, Inc., San Francisco, CA, USA |
| spellingShingle | Vivek Subbiah Ravi Murthy Alexander Guminski Ding Wang Vivek Bhadri Nam Bui Jose Mejia Oneto Kamalesh Sankhala M Wayne Saville Sangeetha Srinivasan Robert Steffner Nathan Yee 416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors Journal for ImmunoTherapy of Cancer |
| title | 416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors |
| title_full | 416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors |
| title_fullStr | 416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors |
| title_full_unstemmed | 416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors |
| title_short | 416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors |
| title_sort | 416 sq3370 001 is a multi center open label phase i dose escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors |
| work_keys_str_mv | AT viveksubbiah 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT ravimurthy 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT alexanderguminski 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT dingwang 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT vivekbhadri 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT nambui 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT josemejiaoneto 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT kamaleshsankhala 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT mwaynesaville 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT sangeethasrinivasan 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT robertsteffner 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors AT nathanyee 416sq3370001isamulticenteropenlabelphaseidoseescalationstudytotestanovelintratumoralandsystemicapproachtotreatadvancedsolidtumors |